Posted by Michael Wonder on 16 Dec 2022
Soligenix announces submission of new drug application to the FDA for HyBryte in the treatment of cutaneous T-cell lymphoma
15 December 2022 - Soligenix announced today that it submitted a new drug application to the US FDA for HyBryte (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma, a rare cancer and area of unmet medical need affecting over 25,000 patients in the US.
HyBryte (SGX301) is a novel, first in class, photodynamic therapy utilising safe, visible light for activation. The active ingredient in HyBryte is synthetic hypericin, a potent photosensitiser that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later.
